文献速递乳腺癌放疗

全乳放疗急性毒性NTCP模型的训练与时间验证

Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques.
PubMed 文献 · Radiother Oncol · 2024-12-25

回顾性纳入1570例全乳放疗(40 Gy/15次)乳腺癌患者,训练队列878例(2009-2017年,三维适形放疗),验证队列692例(2017-2021年,含先进技术)。多变量模型含腋窝淋巴结清扫、高血压和皮肤V20Gy,训练/验证AUC为0.64/0.59,验证队列仅V20Gy的AUC为0.62。

要点

  • 训练队列≥2级毒性14.0%,验证队列17.4%。
  • 模型含腋窝淋巴结清扫、高血压和皮肤V20Gy三个预测因子。
  • 验证队列仅V20Gy的AUC为0.62,校准斜率为0.96(R²=0.6)。

核心结论

  • 训练了中度大分割全乳放疗急性毒性NTCP模型,并进行了时间验证,包括先进照射技术治疗的患者。
  • 验证队列确认了剂量学参数V20Gy的作用,支持皮肤DVH可评估风险并可能改善计划优化的假设。

研究设计与样本

  • 回顾性单中心研究,纳入1570例接受全乳放疗(40 Gy/15次)的乳腺癌患者。
  • 训练队列878例(2009-2017年,三维适形放疗),验证队列692例(2017-2021年,含先进技术)。
  • 验证队列按照射技术分为静态技术组404例和弧形技术组288例。

主要发现

  • 训练队列14.0%、验证队列17.4%的患者发生≥2级毒性。
  • 多变量逻辑回归模型包括腋窝淋巴结清扫(OR=1.58,95%CI=1.01-2.48,p=0.045)、高血压(OR=1.54,95%CI=1.04-2.27,p=0.030)和皮肤V20Gy(OR=1.008,95%CI=1.004-1.013,p<0.0001)。
  • 模型AUC在训练队列为0.64,验证队列为0.59;验证队列仅考虑V20Gy时AUC为0.62。
  • 验证队列校准图斜率为0.96(R²=0.6),Hosmer-Lemeshow拟合优度p=0.99。
  • 验证队列中仅V20Gy的作用得到确认;按静态或弧形技术分析结果相似。

关键数值与推荐

  • 皮肤V20Gy的OR=1.008(95%CI=1.004-1.013,p<0.0001)。
  • 腋窝淋巴结清扫的OR=1.58(95%CI=1.01-2.48,p=0.045)。
  • 高血压的OR=1.54(95%CI=1.04-2.27,p=0.030)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim is to train and validate a multivariable Normal Tissue Complication Probability (NTCP) model predicting acute skin reactions in patients with breast cancer receiving adjuvant Radiotherapy (RT). METHODS AND MATERIALS: We retrospectively reviewed 1570 single-institute patients with breast cancer treated with whole breast irradiation (40 Gy/15fr). The patients were divided into training (n = 878, treated with 3d-CRT, from 2009 to 2017) and validation cohorts (n = 692, treated from 2017 to 2021, including advanced RT techniques). In the validation cohort, patients were classified according to the delivery techniques into static (n = 404) and arc techniques (n = 288). Several clinical/technical information and DVHs of the "skin" (5 mm inner expansion from the body contour) were available. Skin toxicity was assessed during follow-up using the RTOG scale criteria. A multivariable logistic regression model was generated combining skin DVH and clinical parameters, using cross-validation methods that ensured high internal consistency and robustness. The performance of the model was tested in the validation cohort. RESULTS: 14.0 %/17.4 % of patients developed ≥ G2 toxicity, in the training/validation cohorts, respectively. The resulting multivariable logistic model included axillary lymph node dissection (OR = 1.58, 95 %CI = 1.01-2.48, p = 0.045), hypertension (OR = 1.54, 95 %CI = 1.04-2.27, p = 0.030) and skin V20Gy (OR = 1.008, 95 %CI = 1.004-1.013, p < 0.0001). The AUC of the model was 0.64/0.59 in training/validation, with better performance in the validation cohort if considering only V20Gy (0.62). The model showed satisfactory agreement between predicted and observed toxicity rates: in the validation group, the slope of the calibration plot was 0.96 (R2 = 0.6) with excellent goodness-of-fit (Hosmer-Lemeshow p-value = 0.99). Looking at each of the three predictors individually, only the role of V20Gy was confirmed in the validation group. Results were similar when considering patients treated with static or arc techniques. CONCLUSION: An NTCP model for acute toxicity after moderately hypofractionated breast RT was trained. The model underwent temporal validation even for patients treated with advanced delivery techniques. Despite clinical differences and techniques, the confirmation of the dosimetry parameter in the validation cohort highlights its robustness and corroborates the hypothesis that skin DVH may assess the risk with the potential for improving plan optimisation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Vincenzi MM, Cicchetti A, Castriconi R, et al. Training and temporally validating an NTCP model of acute toxicity after whole breast radiotherapy, including the impact of advanced delivery techniques. Radiother Oncol. 2024. PMID: 39725068. doi:10.1016/j.radonc.2024.110700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。